Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
The news archive for Know Labs, Inc. (historically NYSE American: KNW) captures the company’s evolution from a developer of radio frequency dielectric spectroscopy (RFDS) technology for non‑invasive diagnostics to its later transition under the USBC, Inc. name and USBC ticker. Company news releases describe how its RFDS platform directs electromagnetic energy through substances or materials to capture unique molecular signatures, supporting applications such as non‑invasive glucose monitoring and contactless pH measurement.
Readers can review announcements on technology milestones, including laboratory research showing that the company’s RFDS sensor can detect pH changes in real time without direct contact with a liquid, and updates on efforts to advance a non‑invasive blood glucose monitor toward potential FDA clearance. News items also discuss the launch and objectives of Know Labs Technology Licensing (KTL), the division that licenses RFDS technology and the proprietary e‑RFDS© digital watermark to corporations, universities, and research institutions.
The KNW news history further documents significant corporate and capital markets events. These include the 1‑for‑40 reverse stock split effective February 19, 2025, the temporary move to trading on the OTC Pink Market under KNWN while appealing NYSE American delisting proceedings, and subsequent financing and governance developments. Later releases cover the Securities Purchase Agreement with Goldeneye 1995 LLC, the resulting change in control, shareholder approvals to increase authorized common stock and amend the equity incentive plan, and the eventual change of corporate name to USBC, Inc. and trading symbol to USBC.
By browsing this news feed, investors and researchers can trace how Know Labs combined RFDS‑based diagnostic research and licensing with a later strategy that includes a Bitcoin treasury approach and the development of the USBC token, as outlined in joint announcements with Greg Kidd and related SEC filings.
Know Labs, Inc. (NYSE American: KNW) reported its financial results for Q1 2023, revealing a net loss of $3.82 million, a decrease from a $5.36 million loss in Q1 2022. This translates to a loss per share of $0.08, compared to $0.15 the previous year. Research and development expenses surged to $1.74 million from $886,000, attributed to staffing and Bio-RFID technology development aimed at FDA trials. Cash and equivalents decreased to $9.68 million from $12.59 million. The company estimates it has sufficient cash to fund operations until February 14, 2024. Shareholder equity fell to $7.1 million from $9.9 million in the prior quarter.
Know Labs, Inc. (AMEX: KNW) is set to hold a webcast on February 14, 2023, at 1:30 PM PT, to discuss business updates and results from Q1 FY 2023, which ended on December 31, 2022. The webcast will be accessible live and for replay at knowlabs.co/investors. The company specializes in non-invasive medical diagnostic technology, utilizing its Bio-RFID™ technology to develop wearable and mobile diagnostics. Its first product is a non-invasive glucose monitor awaiting FDA clearance. Investors are encouraged to submit questions during the webcast for further insights.
Know Labs, Inc. (NYSE American: KNW) has provided an update on its strategic partnerships to advance the FDA clearance for its innovative non-invasive glucose monitoring devices. The company collaborates with experts in data science, regulatory affairs, and product design, aiming to transform patient care. Key partners include Igor Institute, Bould Design, Edge Impulse, and NOVUS Management Group, who contribute expertise in areas like engineering and algorithm development. Know Labs plans to validate its Bio-RFID technology for accurate glucose measurement in 2023 while continuing to build its advisory board. The non-invasive glucose monitor could revolutionize diabetes management.
Know Labs, Inc. (NYSE American: KNW) announced executive leadership changes aimed at accelerating the development of its Bio-RFID™ technology. Effective immediately, Ron Erickson, the founder, has been appointed CEO, bringing nearly 20 years of experience. Masanori King Takee is now Chief Technology Officer, focusing on software and data science to refine Bio-RFID algorithms. Jessica English joins as Chief Marketing Officer to lead marketing efforts, while Leo Trautwein is promoted to Chief Commercial Officer. The company aims to validate its technology through data science and partnerships for clinical trials in 2023.
Know Labs, Inc. (NYSE American: KNW) has appointed founder Ron Erickson as the new CEO, succeeding Phil Bosua, who transitions to a technology advisor role. Erickson, with nearly 20 years at Know Labs and over 30 years in leadership roles, emphasized the importance of accelerating product development for the Bio-RFID technology, aimed at non-invasive glucose monitoring. The company is focused on FDA clearance and enhancing its product development team in 2023. The Board supports this leadership change, highlighting an aggressive strategy to transform medical diagnostics and enhance shareholder value.
Know Labs, Inc. (AMEX: KNW) has been granted a new foundational patent for its Bio-RFID diagnostic technology, establishing a superior benchmark range of clinical accuracy (MARD) for glucose monitoring. This patent extends its intellectual property portfolio to nearly 90 patents, solidifying its position in non-invasive glucose monitoring. The patented MARD range of 5.0% to 9.9% sets it apart from existing glucose monitoring devices. Know Labs aims to become a reference standard in glucose testing, with plans to continue its FDA clearance process for its non-invasive glucose monitoring device.
Know Labs, Inc. (KNW) reported financial results for the fiscal year ending September 30, 2022, highlighting consolidated revenues of $4.360 million. The R&D expenses surged to $5.386 million from the prior year’s $3.970 million, driven by staffing and technological advancements. The net loss for the year stood at $20.071 million, a decrease from $25.360 million in 2021. Cash and equivalents remained stable at $12.594 million. Current assets exceeded current liabilities, indicating a healthy current ratio of 3.61 compared to 1.17 in 2021.
Know Labs, Inc. (AMEX:KNW) addressed recent false claims from a research firm linked to short-selling. The company remains confident in its Bio-RFID™ technology for non-invasive glucose monitoring, aiming for FDA clearance. Founder Ron Erickson criticized the motives of those spreading misinformation for financial gain, asserting the uniqueness of their technology in the diagnostics field. Know Labs is set to report its Q4 and fiscal year 2022 results today, following a recent presentation to institutional investors.
Know Labs, Inc. (AMEX: KNW) will host a webcast on December 20, 2022, at 1:30 PM PT to review updates and results for its fiscal year ending September 30, 2022. The public can access the live audio webcast through the company's investor relations website. Know Labs focuses on developing non-invasive medical diagnostic technology, including a patented Bio-RFID™ technology for identifying analytes without invasive tests. The first application will be a non-invasive glucose monitor, pending FDA clearance.
Know Labs, Inc. (NYSE AMERICAN: KNW) will present at the Bernstein CGM Disruptors Conference on November 18, 2022. The company will update its Bio-RFID technology, aimed at non-invasive glucose monitoring. Bio-RFID uses radio-frequency spectroscopy to detect analytes in the bloodstream, with the first application being a glucose monitor that provides real-time blood glucose levels. This product requires FDA approval before market introduction. Know Labs focuses on integrating its technology into wearable devices for better health monitoring.